drugset
drugset / Trial / NCT02184429

A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions

NCT02184429 ↗

Phase 1 Completed 56 enrolled Pfizer
RandomizedParallel-groupDouble-blindBasic science

Summary

This study is designed to evaluate the safety and plasma concentrations of PF-06669571 in healthy volunteers following single and multiple ascending doses of PF-06669571. Effect of food on PF-06669571 plasma concentrations will be be evaluated after a single dose of PF-06669571. During multiple dose phase, PF-06669571 will be administered daily for 14 days

Timeline

Start
2014-07
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject RAZPIPADON Small molecule 0.15 mg Oral
Subject RAZPIPADON Small molecule 0.2 mg Oral
Subject RAZPIPADON Small molecule 0.4 mg Oral
Subject RAZPIPADON Small molecule 0.5 mg Oral
Subject RAZPIPADON Small molecule 0.75 mg Oral
Subject RAZPIPADON Small molecule 1.5 mg Oral
Subject RAZPIPADON Small molecule 3 mg Oral
Subject RAZPIPADON Small molecule 4.5 mg Oral
Subject RAZPIPADON Small molecule 6 mg Oral
Subject RAZPIPADON Small molecule 9 mg Oral
Subject RAZPIPADON Small molecule 10 mg Oral

Indications

No indication recorded.